On 14 October 2016, orphan designation (EU/3/16/1742) was granted by the European Commission to Therapicon Srl, Italy, for acebutolol hydrochloride for the treatment of Smith-Magenis syndrome.
The sponsorship was transferred to Worphmed S.r.l., Italy in March 2019.
|Disease / condition||
Treatment of Smith-Magenis syndrome
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;